Compare ARMOUR Residential REIT, Inc. (ARR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.72 (market cap $2.07B), while State Street SPDR S&P Biotech ETF trades at $158.26. The key difference: ARMOUR Residential REIT, Inc. pays a 17.28% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ARMOUR Residential REIT, Inc. nearer its low. Which is the better fit depends on your goals.
| ARR | XBI | |
|---|---|---|
Market Cap | $2.07B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $19.12 | $164.28 |
52-Week Low | $14.05 | $86.92 |
Dividend Yield | 17.28% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
